REGENXBIO enters into $150M ATM equity offering agreement with BofA Securities

REGENXBIO Inc.

May offer and sell common stock up to $150M aggregate price under ATM Sales Agreement with BofA Securities.
Agent will receive commission up to 3% of gross proceeds; sales made at prevailing market prices.
Company not obligated to sell any shares; agreement may terminate at any time by either party.
Offering complements existing S-3 shelf registration filed December 30, 2022.
BofA has provided and may continue providing investment banking and financial services to REGENXBIO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.